$388 Hammond Manufacturing TRANSFORMER AUDIO 48CT/8 106R (Pack of 10) Electronics Power Accessories $388 Hammond Manufacturing TRANSFORMER AUDIO 48CT/8 106R (Pack of 10) Electronics Power Accessories AUDIO,Electronics , Power Accessories,/challengee533866.html,48CT/8,106R,of,Hammond,$388,TRANSFORMER,(Pack,collegiumtalentum.com,Manufacturing,10) Hammond Manufacturing TRANSFORMER AUDIO 48CT 8 of 106R 10 Pack Max 59% OFF Hammond Manufacturing TRANSFORMER AUDIO 48CT 8 of 106R 10 Pack Max 59% OFF AUDIO,Electronics , Power Accessories,/challengee533866.html,48CT/8,106R,of,Hammond,$388,TRANSFORMER,(Pack,collegiumtalentum.com,Manufacturing,10)

Hammond Manufacturing TRANSFORMER AUDIO 48CT 8 of Japan Maker New 106R 10 Pack Max 59% OFF

Hammond Manufacturing TRANSFORMER AUDIO 48CT/8 106R (Pack of 10)

$388

Hammond Manufacturing TRANSFORMER AUDIO 48CT/8 106R (Pack of 10)

|||

Product description

106R Hammond Manufacturing Transformers DigiKey

TRANSFORMER AUDIO 48CT/8

Features:

  • Part Status:-Active
  • Turns Ratio - Primary:Secondary:--
  • Impedance - Primary (Ohms):-48CT
  • Impedance - Secondary (Ohms):-8
  • DC Resistance (DCR) - Primary:-2.4 Ohm
  • DC Resistance (DCR) - Secondary:-700 mOhm
  • Transformer Type:-Miniature Epoxy Potted
  • Frequency Range:-170Hz
  • Frequency Response:--1dB
  • Voltage - Isolation:-200V
  • Insertion Loss:-1dB
  • Return Loss:--
  • Environmental amp; Export Classification:

  • Lead Free Status / RoHS Status Lead free / RoHS Compliant Moisture Sensitivity Level (MSL) Not Applicable
  • Hammond Manufacturing TRANSFORMER AUDIO 48CT/8 106R (Pack of 10)

    CURRENT ISSUE
    September, 2021

    No. 106 (9)

    2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
    ARTICLES IN THREE SENTENCES
    Article

    Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

    This open-label, single-arm study investigated the long-term efficacy of tafasitamab plus lenalidomide in 81 patients with relapsed/refractory diffuse large B-cell lymphoma. The response rate was 57.5%, including complete responses in 40.0% of patients, and the median duration of response was 43.9 months. This treatment is a valuable option for patients not eligible for autologous stem-cell transplantation.

    Johannes Duell et al.

    Case Report

    Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients

    Grey zone lymphoma is a B-cell lymphoma, unclassifiable, with features intermediate between those of large B-cell lymphoma and classic Hodgkin lymphoma. The in-depth study of the two adolescent patients described in this case report expands the clinicopathological and genomic spectrum of this rare pediatric disease. Moreover, it provides information on their response to treatment.

    Cagla Y. Benkli et al.

    Article

    CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients

    The clinical picture of 56 patients with congenital amegakaryocytic thrombocytopenia due to MPL mutations was much more varied than previously thought. Twenty-five per cent of them had no signs of thrombocytopenia at birth, and 50% had non-hematologic defects. Pancytopenia developed in (nearly) all patients and hematopoietic stem-cell transplantation was effective in 87% of cases.

    Manuela Germeshausen et al.

    Article

    Oxidative stress activates red cell adhesion to laminin in sickle cell disease

    Sickle red blood cells exhibit abnormal adhesion to laminin mediated by Lu/BCAM protein at their surface. This study provides evidence of the involvement of oxidative stress in post-translational modifications of Lu/BCAM which impact the protein’s distribution and cis-interaction with glycophorin C at the cell surface activating its adhesive function in dense sickle red cells. The authors speculate that antioxidant drugs might attenuate this phenomenon.

    Maria Alejandra Lizarralde-Iragorri et al.

    TAKE ADVANTAGE FROM HAEMATOLOGICA